Independent register of U.S. FDA drug recalls · updated Oct 11, 2026
RxRecalls Get alerts

FDA Drug Recalls

18,003 recalls, newest first

Class II · Moderate risk

Losartan Potassium Tablets

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-0503-2019
Class II · Moderate risk

Losartan Potassium Tablets

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-0502-2019
Class II · Moderate risk

Losartan Potassium Tablets

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-0501-2019
Class I · High risk

Ceftriaxone for Injection USP

Presence of Particulate Matter: Product complaints received of grey flecks, identified as shredded rubber particulate matter from the stopper observed in reconstituted vials.

Terminated Particulate / foreign matter Lupin Pharmaceuticals Inc. NDC 68180-644-01 D-0358-2019
Class I · High risk

Ceftriaxone for Injection USP

Presence of Particulate Matter: Product complaints received of grey flecks, identified as shredded rubber particulate matter from the stopper observed in reconstituted vials.

Terminated Particulate / foreign matter Lupin Pharmaceuticals Inc. NDC 68180-633-01 D-0357-2019
Class I · High risk

Ceftriaxone for Injection USP

Presence of Particulate Matter: Product complaints received of grey flecks, identified as shredded rubber particulate matter from the stopper observed in reconstituted vials.

Terminated Particulate / foreign matter Lupin Pharmaceuticals Inc. NDC 68180-622-01 D-0356-2019
Class I · High risk

Ceftriaxone for Injection USP

Presence of Particulate Matter: Product complaints received of grey flecks, identified as shredded rubber particulate matter from the stopper observed in reconstituted vials.

Terminated Particulate / foreign matter Lupin Pharmaceuticals Inc. NDC 68180-611-01 D-0355-2019
Class II · Moderate risk

Oxygen

CGMP Deviations

Terminated cGMP deviation Roberts Home Medical LLC D-1002-2019
Class II · Moderate risk

Cidofovir Dihydrate

CGMP Deviations: Active Pharmaceutical Ingredient (API) manufacturer is on FDA Import Alert.

Terminated cGMP deviation LGM Pharma LLC D-0486-2019

Recalls by year